<DOC>
	<DOC>NCT01868542</DOC>
	<brief_summary>This trial is conducted in Asia. The aim of the trial is to compare the glycaemic control of Levemir® (insulin detemir) administered once daily according to two titration algorithms after 20 weeks in subjects with type 2 diabetes inadequately controlled on metformin treatment with or without other anti-diabetic drugs (OADs).</brief_summary>
	<brief_title>A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Diagnosed with type 2 diabetes mellitus at least 3 months prior to Visit 1 (week 2) Treatment with at least 1000 mg metformin per day with/without other OADs at a stable dose (at either the maximal tolerated dose or at least half of the maximum recommended dose according to the package insert) for at least 3 months prior to Visit 1 Insulinnaïve subjects HbA1c above or equal to 7.5% by central laboratory analysis Body mass index (BMI) below or equal to 35.0 kg/m^2 Female who is breastfeeding The receipt of any investigational product within 4 weeks prior to Visit 1 Any contraindication to insulin detemir according to the domestic labelling Anticipated change of dose of any systemic treatment with products, which in the investigator's opinion could interfere with glucose metabolism (such as systemic corticosteroids, betablockers, monoamine oxidase [MAO] inhibitors) Clinically significant diseases which, in the investigator's opinion, may confound the results of the trial or pose additional risk in administering trial product Any conditions that the investigator judges would interfere with trial participation or evaluation of the results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>